Does Rallies show 13F holders for INSM?

Yes. Rallies tracks hedge fund and 13F ownership data for INSM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is INSM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INSM. It does not provide personalized investment advice.

INSM (Insmed) Stock Analysis - Hedge Fund Holdings

Insmed (INSM) is a publicly traded Healthcare sector company. As of May 21, 2026, INSM trades at $107.56 with a market cap of $23.23B and a P/E ratio of -18.64. INSM moved +0.37% today. Year to date, INSM is -38.41%; over the trailing twelve months it is +57.51%. Its 52-week range spans $60.40 to $212.75. Analyst consensus is strong buy with an average price target of $203.20. Rallies surfaces INSM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns INSM stock?

Hedge funds tracked by Rallies that own INSM include Duquesne Family, Viking Global, Maverick Capital, Soros Fund, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Insmed.

INSM Key Metrics

Key financial metrics for INSM
Metric	Value
Price	$107.56
Market Cap	$23.23B
P/E Ratio	-18.64
EPS	$-5.74
Dividend Yield	0.00%
52-Week High	$212.75
52-Week Low	$60.40
Volume	2.61M
Avg Volume	0
Revenue (TTM)	$819.56M
Net Income	$-1.18B
Gross Margin	81.81%

Top Hedge Funds Holding INSM

Duquesne Family holds 1.15M shares of INSM, changed -22.11% as of Mar 31, 2026.
Viking Global holds 1.04M shares of INSM, changed +0.00% as of Jun 30, 2024.
Maverick Capital holds 656.54K shares of INSM, changed -18.35% as of Sep 30, 2025.
Soros Fund holds 307.21K shares of INSM, changed -32.49% as of Mar 31, 2025.
Bridgewater Associates holds 295.58K shares of INSM, changed +0.00% as of Mar 31, 2026.

Latest INSM News

Insmed Target Cut to $185 Signals 58.7% Upside Despite 23% Q1 Revenue Miss — May 13, 2026
Insmed slides after May 7 Q1 results show revenue miss despite reiterated guidance — May 7, 2026
Insmed Q1 Revenues Reach $306M with 44% BRINSUPRI Surge and TPIP Progress — May 7, 2026
Insmed and Ty Pennington Launch Suspect Bronchiectasis Campaign for 500,000 Patients — May 6, 2026
Insmed rises ahead of May 7 Q1 results, as pre-earnings positioning builds — May 4, 2026

Recent INSM Insider Trades

Flammer Martina M.D. sold 10.48K (~$1.23M) on May 14, 2026.
Bonstein Sara sold 8.27K (~$961.04K) on May 13, 2026.
Adsett Roger sold 5.84K (~$678.14K) on May 13, 2026.

INSM Analyst Consensus

16 analysts cover INSM: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $203.20.

Common questions about INSM

Who owns INSM stock?: Hedge funds tracked by Rallies that own INSM include Duquesne Family, Viking Global, Maverick Capital, Soros Fund, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Insmed.
Does Rallies show 13F holders for INSM?: Yes. Rallies tracks hedge fund and 13F ownership data for INSM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is INSM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INSM. It does not provide personalized investment advice.